Shukla Sath 4
4 · Spero Therapeutics, Inc. · Filed Aug 6, 2024
Insider Transaction Report
Form 4
Shukla Sath
CEO & President
Transactions
- Sale
Common Stock
2024-08-02$1.32/sh−14,800$19,536→ 1,161,207 total - Sale
Common Stock
2024-08-05$1.31/sh−17,641$23,110→ 1,143,566 total
Footnotes (1)
- [F1]The reported transaction is a sale of common stock effected to cover tax withholding obligations in connection with the vesting of RSUs that were granted to the Reporting Person on August 1, 2023 pursuant to a "sell to cover" provision included in each RSU Agreement.